Aripiprazole in schizophrenia: Consensus guidelines

International Journal of Clinical Practice

Volumn 59, Issue 4, 2005, Pages 485-495

  Travis, M J ^a   Burns, T ^b   Dursun, S ^c   Fahy, T ^a   Frangou, S ^a   Gray, R ^a   Haddad, P M ^d   Hunter, R ^e   Taylor, David M ^f   Young, A H ^g  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d Cromwell House   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^g Infirmary   (United Kingdom)

Author keywords

Aripiprazole; Dopamine System stabilisers; NICE guidance; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CINNARIZINE; CLOZAPINE; DOXAZOSIN; FLUOXETINE; HALOPERIDOL; INDORAMIN; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PHENTOLAMINE; PRAZOSIN; QUETIAPINE; RISPERIDONE; TERAZOSIN; VALPROIC ACID; ZIPRASIDONE; ZOTEPINE;

AKATHISIA; ANXIETY DISORDER; ARTICLE; BODY WEIGHT DISORDER; CHRONIC DISEASE; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONSENSUS DEVELOPMENT; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG USE; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GOOD CLINICAL PRACTICE; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; HYPOGONADISM; INFERTILITY; INSOMNIA; LIBIDO DISORDER; LONG TERM CARE; NAUSEA; OSTEOPOROSIS; OVARY INSUFFICIENCY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; RESTLESSNESS; SCHIZOPHRENIA; TREMOR; UNITED KINGDOM; VOMITING; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CONSENSUS; DRUG INTERACTIONS; HEART DISEASES; HUMANS; HYPERTENSION; MENTAL DISORDERS; METABOLIC DISEASES; PATIENT COMPLIANCE; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 20144386748     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00498.x     Document Type: Article

References (32)

1. National Institute for Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance No. 43, London, 2002.
2. Otsuka Pharmaceuticals (UK) Ltd. Summary of Product Characteristics - Abilify, 2004.
3. Bristol-Myers Squibb Pharmaceuticals. Aripiprazole - Summary Hounslow: BMS, 2004.
4. Sanofi Synthelabo. Summary of Product Characteristics - Solian, 2004.
5. Novartis Pharmaceuticals UK Ltd. Summary of Product Characteristics - Clozaril, 2002.
6. Eli Lilly Ltd. Prescribing Information - Zyprexa 2004.
7. AstraZeneca UK Ltd. Summary of Product Characteristics - Seroquel, 2003.
8. AstraZeneca Pharmaceuticals LP. Prescribing Information - Seroquel, 2004.
9. Janssen-Cilag Ltd. Summary of Product Characteristics - Risperdal, 2004.
10. Pfizer. Summary of Product Characteristics - Geodon, 2001.
11. Orion Pharma (UK) Ltd. Summary of Product Characteristics - Zoleptil, 2002.
12. Kasper S, Lerman MN, McQuade RD et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6: 325-37.
13. Potkin SG, Saha AR, Kukawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-90.
14. Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763-71.
15. Pigott TA, Carson WH, Saha AR et al. Aripiprazole for the prevention of relapse in stabilised patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003; 64 1048-56.
16. Daniel DG, Saha AR, Ingenito G et al. Aripiprazole: a novel antipsychotic: overview of a phase II study result. Int J Neuropsychopharmacol 2000; 3 (Suppl.): S157.
17. Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a new atypical antipsychotic: phase 2 clinical trial results. Eur Neuropsychopharmacol 1997; 7 (Suppl.): S227.
18. Lieberman J, Carson WH, Saha AR et al. Meta-analysis of the efficacy of aripiprazole in schizophrenia. Int J Neuropsychopharmacol 2002; 5 (Suppl.): S186.
19. Casey DE, Carson WH, Saha AR et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003; 166: 391-9.
20. Tandon R, Stock EG, Kujawa MJ et al. Broad effectiveness trial with aripiprazole. Poster Presented at American Psychiatric Association 55th Institute on Psychiatric Services, October/November 2003, Boston, MA, USA.
21. McQuade RD, Jody DN, Kukawa MJ et al. Long-term weight effects of aripiprazole vs olanzapine. Presented at: American Psychiatric Association 156th annual meeting, May 2003, San Francisco, CA, USA.
22. Total Patient Tracker (TPT), Verispan, L.L.C., January 2003-June 2004. The claim is based on the projected number of unique patients who filled a prescription for Abilify in the U.S. from January 2003-June 2004. The unique patient count is cumulative of all patients who filled a prescription for Abilify within the 18 months ending June 2004.
23. Marder SR, McQuade RD, Stock E et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability; in short-term, placebo-controlled trials. Schizophr Res 2003; 61: 123-36.
24. Jody D, Saha AR, Iwamoto T et al. Meta-analysis of weight effects with aripiprazole. Int J Neuropsychopharmacol 2002; 5 (Suppl.): S186.
25. Kujawa M, McQuade R, Jody D et al. Long-term weight effects of aripiprazole versus olanzapine in a 26-week double-blink study. Int J Neuropsychopharmacol 2004; 7 (Suppl.): S234.
26. Wieck A, Haddad PM. Antipsychotic induced-hyperprolactinaemia in women: pathophysiology, severity and consequences. Br J Psychiatry 2004; 182: 199-204.
27. Carson WH, Saha AR, Iwamoto T et al. Meta-analysis of prolactin effects with aripiprazole. Int J Neuropsychopharmacol 2002; 5 (Suppl.): S186.
28. Stock E, Saha A, Brunell R et al. Meta-analysis of cardiac safety with aripiprazole. Int J Neuropsychopharmacol 2002; 5 (Suppl.): S186.
29. Modell S, Wilber R, Marcus R et al. Efficacy and safety of intramuscular aripiprazole. Presented at Royal College of Psychiatrists annual meeting, July 2004, Harrogate, UK.
30. Saha AR, Brown D, McEvoy J et al. Tolerability and efficacy of aripiprazole patients with first-episode schizophrenia: an open-label pilot study. Presented at 12th Biennial Winter Workshop on Schizophrenia, February 2004, Davos, Switzerland.
31. Markovitz P. The Avon Mental Health Measure Bristol: Changing Minds, 1996.
32. Taylor DM, McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 2000; 101: 416-132.